Eli Lilly is collaborating with Nvidia to build “the most powerful supercomputer owned and operated by a pharmaceutical company.”
The system will power an “AI factory” — a computing infrastructure designed to manage the entire AI lifecycle from data ingestion to high-volume inference, according to an Oct. 28 news release. It will be the first Nvidia DGX SuperPOD using DGX B300 systems and will run on more than 1,000 B300 GPUs, or graphics processing units, connected through a unified high-speed network.
The technology is intended to accelerate drug discovery and development by enabling scientists to train AI models on millions of experiments. Eli Lilly also plans to use the system in medical imaging, manufacturing and enterprise-level AI agent development.
The supercomputer will be powered entirely by renewable electricity and cooled using Eli Lilly’s existing chilled water infrastructure to comply with the company’s sustainability commitments, according to the release.
